CA
PNT

Claro Advisors’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Claro Advisors’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,920
Closed -$72.8K – 418
2023
Q3 		$72.8K Sell
10,920
-186
-2% -$1.55K 0.02% 366
2023
Q2 		$101K Sell
11,106
-214
-2% -$1.89K 0.03% 367
2023
Q1 		$82.3K Sell
11,320
-500
-4% -$3.71K 0.02% 346
2022
Q4 		$86.2K Sell
11,820
-4,100
-26% -$30.4K 0.03% 310
2022
Q3 		$108K Hold
15,920
– – 0.04% 269
2022
Q2 		$108K Sell
15,920
-7,380
-32% -$56.5K 0.04% 269
2022
Q1 		$130K Hold
23,300
– – 0.05% 275
2021
Q4 		$130K Buy
23,300
+8,000
+52% +$60K 0.05% 275
2021
Q3 		$118K Sell
15,300
-550
-3% -$5.02K 0.05% 248
2021
Q2 		$163K Buy
15,850
+450
+3% +$4.58K 0.07% 227
2021
Q1 		$162K Buy
+15,400
New +$209K 0.08% 209

Other funds holding PNT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Claro Advisors's PNT Position: Q4 2023 in Review

Claro Advisors sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 10,920 shares — an estimated $72.8K sold.

Claro Advisors first reported a position in PNT in Q1 2021 and held it in 11 quarters. The position peaked at $163K in Q2 2021. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

  • Claro Advisors reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Claro Advisors sold 10,920 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $72.8K.
  • Claro Advisors first reported a position in POINT Biopharma Global Inc. Common Stock in Q1 2021 and held it in 11 quarters.
  • Claro Advisors's POINT Biopharma Global Inc. Common Stock position peaked at $163K in Q2 2021.
  • 1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Claro Advisors's 13F filing for Q4 2023, filed 22 Jan 2024.